Evidence map›Paper›PMID 25852210›Full record

Trial reportDiabetes care2015

Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort.

Kelly J Hunt, Nathaniel L Baker, Patricia A Cleary, Richard Klein, Gabriel Virella, Maria F Lopes-Virella, DCCT/EDIC Group of Investigators

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Novel Insights into the Molecular Mechanisms of Atherosclerosis.International journal of molecular sciences · 2023
    Review
  11. Observational
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kelly J HuntDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC Ralph H. Johnson VA Medical Center, Charleston, SC huntke@musc.edu.
Nathaniel L BakerDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC.
Patricia A ClearyThe Biostatistics Center, The George Washington University, Washington, DC.
Richard KleinRalph H. Johnson VA Medical Center, Charleston, SC Department of Medicine and Laboratory Services, Medical University of South Carolina, Charleston, SC.
Gabriel VirellaDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.
Maria F Lopes-VirellaRalph H. Johnson VA Medical Center, Charleston, SC Department of Medicine and Laboratory Services, Medical University of South Carolina, Charleston, SC.
DCCT/EDIC Group of Investigators
Medical University of South Carolina · USRalph H. Johnson VA Medical Center · USGeorge Washington University · US

Funding

Limited Competition for the Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Clinical Research Center (Collaborative U01)U01DK094157 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Ionut Bebu, Barbara Halina Braffett · 2011 to 2026
$97.6M
SECRETED ADIPOCYTE PROTEINS, INSULIN RESISTANCE VASCULARP01HL055782 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LOPES-VIRELLA, MARIA F · 1996 to 2005
$8.9M
Biomarkers of Vascular Disease Progression in Type 1 Diabetes MellitusR01DK081352 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LOPES-VIRELLA, MARIA F · 2008 to 2011
$2.2M
Longitudinal Assessment of LDL Immune Complexes and Type 1 Diabetes ComplicationsR01DK088778 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HUNT, KELLY J · 2010 to 2011
$336k
NHLBI NIH HHS P01 HL055782NHLBI NIH HHS P0NID1-HL55782NIDDK NIH HHS R01 DK081352NIDDK NIH HHS R01-DK081352NIDDK NIH HHS R01 DK088778NIDDK NIH HHS R01-DK088778NIDDK NIH HHS U01 DK094157
6 · The paper itself

Abstract

objectiveThere is considerable interest in identifying biomarkers that predict high risk for the development of macrovascular complications in patients with diabetes. Therefore, the longitudinal association between subclinical atherosclerosis as measured by internal carotid artery intima-media thickness (IMT) and acute-phase reactants, cytokines/adipokines, thrombosis, and adhesion molecules was examined. RESEARCH DESIGN AND

methodsBiomarkers were measured at four time points over 20 years in 886 DCCT/EDIC participants with type 1 diabetes. Four composite scores were created by combining z scores generated from within the data set of individual biomarkers: acute-phase reactants (fibrinogen, C-reactive protein), thrombosis (fibrinogen, active and total plasminogen activator inhibitor [PAI]-1), cytokines/adipokines (tumor necrosis factor receptor-1 and -2, active and total PAI-1, IL-6), and endothelial dysfunction (soluble intracellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble E-selectin). Internal carotid IMT was measured at EDIC years 1, 6, and 12, with elevated IMT defined at each time point as being in the upper quintile of its distribution.

resultsLogistic regression models indicate that while individual biomarkers were not predictive of or associated with subclinical atherosclerosis, composite scores of acute-phase reactants (odds ratio [OR] 2.78 [95% CI 1.42, 5.42]), thrombolytic factors (OR 2.83 [95% CI 1.45, 5.52]), and cytokines/adipokines (OR 2.83 [95% CI 1.48, 5.41]) measured at our final time point EDIC years 8-11 were associated with higher levels of atherosclerosis at EDIC year 12, but findings were not consistent at early time points. The endothelial dysfunction score was not appreciably predictive of or associated with subclinical atherosclerosis at any of the time points measured.

conclusionsThe pathophysiologic relationship between higher biomarker levels and progression of subclinical atherosclerosis remains unclear.

Indexed as

AdultAtherosclerosisBiomarkersBlood CoagulationCarotid Intima-Media ThicknessC-Reactive ProteinDiabetes Mellitus, Type 1Diabetic AngiopathiesDisease ProgressionEndothelium, VascularE-SelectinFemaleHumansInflammationInterleukin-6MaleBiomarkersC-Reactive ProteinE-SelectinInterleukin-6Plasminogen Activator Inhibitor 1SERPINE1 protein, humanVascular Cell Adhesion Molecule-1

Identifiers

PMID25852210
PMCPMC4477339
OpenAlexW2155774353

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.